{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-331556","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2026-08-04T11:30:19+00:00","discovered_at":"2026-08-04T11:35:01.377104+00:00","generated_at":"2026-08-04T11:35:30.768774+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palvella reports Q2 net loss $21.9M; submits first NDA module for QTORIN rapamycin","bullets":["Net loss $21.9M ($1.52/share) vs $9.5M ($0.86) in Q2 2025; R&D spend $12.5M (up from $5.1M).","Cash, equivalents, and short-term investments $250.6M as of June 30, 2026.","Submitted first module of rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations; completion on track for H2 2026.","Planned U.S. commercial launch in H1 2027 if approved; Phase 3 trial for cutaneous venous malformations planned for Q4 2026.","Appointed Matt Pauls to Board; uplisted to Nasdaq Global Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-331556","json":"https://secwatch.observer/filing/0001193125-26-331556.json","markdown":"https://secwatch.observer/filing/0001193125-26-331556.md","text":"https://secwatch.observer/filing/0001193125-26-331556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/0001193125-26-331556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:35:30.768774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}